https://noctrixhealth.com/news/noctrix-health-inc-completes-17m-million-series-b-financing/2023-08-21T22:24:16+00:00https://noctrixhealth.com/news/noctrix-health-granted-fda-breakthrough-device-designation-for-wearable-restless-legs-syndrome-therapy/2023-08-21T22:24:00+00:00https://noctrixhealth.com/news/noctrix-health-announces-enrollment-of-first-patient-in-the-restful-study-and-publication-of-positive-pilot-study-results/2023-08-21T22:23:41+00:00https://noctrixhealth.com/news/noctrix-health-announces-successful-randomized-controlled-trial-rct-outcomes-and-fda-marketing-authorization-for-its-breakthrough-tonic-motor-activation-tomac-restless-legs-syndrome-rls-therapy/2023-08-21T22:23:06+00:00https://noctrixhealth.com/news/noctrix-health-announces-publication-of-landmark-results-from-randomized-clinical-trial-and-long-term-extension-study-of-its-revolutionary-tonic-motor-activation-tomac-therapy-for-restless-legs-synd/2024-12-04T22:39:34+00:00https://noctrixhealth.com/news/noctrix-health-announces-favorable-inclusion-of-nidra-tonic-motor-activation-tomac-therapy-in-new-american-academy-of-sleep-medicine-aasm-clinical-practice-guidelines-for-restless-legs-syndrome-r/2024-12-04T22:44:55+00:00https://noctrixhealth.com/news/noctrix-health-announces-new-cms-reimbursement-codes-and-payment-for-nidra-tonic-motor-activation-tomac-therapy-for-restless-legs-syndrome-rls/2024-12-04T22:46:17+00:00https://noctrixhealth.com/news/noctrix-health-raises-33-5m-and-expands-leadership-team-to-accelerate-u-s-commercialization-of-nidrar-therapy-for-restless-legs-syndrome-rls/2025-09-19T14:43:11+00:00